Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

TELESTA THERAPEUTICS INC T.TST

"Telesta Therapeutics Inc is a biopharmaceutical company. The Company is engaged in the research, development, manufacturing and commercialization of human health products and technologies."


TSX:TST - Post by User

Post by noinstinct89on Jan 20, 2016 8:01am
202 Views
Post# 24475551

"FDA Late-Cycle Meeting"

"FDA Late-Cycle Meeting"
I just googled "FDA Late Cycle Meeting Drug Approval".... If you look into the Google News (2015-2013) you can see that this late cycle Meeting with other drug companies was held before they had their AdComs for their drugs. So why in the world TST had this Meeting AFTER their Adcom? Did someone notice this??? Who can explain? https://ecghealthcare.com/whitepaper/white-paper.html https://www.raps.org/Regulatory-Focus/News/2015/10/07/23340/Regulatory-Recon-Califf-Removes-Name-From-Papers-Following-Nomination-7-October-2015/ Want to hear a secret? The Late-Cycle Review meeting is a critical opportunity to positively position your company, clarify important concerns, and prepare for your upcoming Advisory Committee meeting. By streamlining product communication with the FDA, successful drug developers are cutting approval times and improving AdComm meetings. ECG has written a comprehensive white paper with the key principles & practices that should be part of any Late-Cycle Review meeting preparation. Download the free white paper.
<< Previous
Bullboard Posts
Next >>